Table 1.
Cohort demographics and baseline labs at ART initiation
| HIV mono-infecteda n=1,352 | HIV/HCV+b n=79 | P valuec | |
|---|---|---|---|
| Female, n (%) | 0.38 | ||
| Median age, years (IQR) | 35 | 39 | <0.0001 |
| WHO Stage, n (%) | 0.50 | ||
| 1 | 37 | 33 | |
| 2 | 45 | 46 | |
| 3 | 14 | 19 | |
| 4 | 4 | 2 | |
| Drug Regimen, n (%) | |||
| NVP-containing | 95 | 94 | 0.80 |
| d4T-containing | 51 | 53 | 0.73 |
| Baseline median CD4 count, cells/mm3 (IQR) | 135 | 115 | 0.43 |
| Baseline median HIV RNA, log cp/ml (IQR) | 4.8 | 4.9 | 0.12 |
| Baseline median ALT, U/ml (IQR) | 19.1 | 27.3 | 0.008 |
| ALT >5x ULN, n (%) | 0.23 | 0 | 1.00 |
a
183 were HCV antibody positive and HCV RNA <42; 1169 were HCV antibody negative
b
HCV antibody positive and detectable HCV RNA
c
p-values represent comparison between HIV-mono-infected and HIV-HCV co-infected subjects